A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

Author(s):
Rouwendal, G.J.A.; Lee, M.M. van der; Meyer, S.; Reiding, K.R.; Schouten, J.; Roo, G. de; Egging, D.F.; Leusen, J.H.W.; Boross, P.; Wuhrer, M. (0000-0002-0814-4995); Verheijden, G.F.; Dokter, W.H.; Timmers, M.; Ubink, R.
Published
2016
Publication type
Article / Letter to editor
cysteine mutationHER2monoclonal IgA antibodyN-glycan sialylationpharmacokineticstransgenic FcRI mouse model
Date issued
2016-01-02
Language
English
Is part of
mAbs (2016), Vol. 8, no. 1, p. 74-86
hdl
1887/101801
doi
10.1080/19420862.2015.1102812